Idiopathic pulmonary fibrosis (IPF) is a highly heterogeneous, unpredictable and ultimately
lethal chronic lung disease. Over the last decade, two anti-fibrotic agents have been shown …

Rationale, aims, and objectives The 6‐minute walk test (6MWT) is widely used as a test of
functional exercise capacity. Several studies have reported the minimal clinically important …

Within the spectrum of fibrosing interstitial lung diseases (ILDs) is a subset of patients who
have inexorable progression of pulmonary fibrosis despite treatment, which is known as the …

Background No therapies are currently approved for the treatment of pulmonary
hypertension in patients with interstitial lung disease. The safety and efficacy of inhaled …

Background In the absence of research into therapies and care pathways for long COVID,
guidance based on 'emerging experience'is needed. Aim To provide a rapid expert guide for …

Background In two of three phase 3 trials, pirfenidone, an oral antifibrotic therapy, reduced
disease progression, as measured by the decline in forced vital capacity (FVC) or vital …

The appropriate selection of lung transplant recipients is an important determinant of
outcomes. This consensus document is an update of the recipient selection guidelines …

Objective In prior open‐label studies, eteplirsen, a phosphorodiamidate morpholino
oligomer, enabled dystrophin production in Duchenne muscular dystrophy (DMD) with …

Background Idiopathic pulmonary fibrosis is a progressive lung disease with a high mortality
rate. Because the signaling pathways activated by several tyrosine kinase receptors have …